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A B S T R A C T
Background: Silymarin, a hepatoprotective agent, has poor oral bioavailability. However, the current
dosage form of the drug does not target the liver and inﬂammatory cells selectively. The aim of the
present study was to develop lecithin-based carrier system of silymarin by incorporating phytosomal–
liposomal approach to increase its oral bioavailability and to make it target-speciﬁc to the liver for
enhanced hepatoprotection.
Methods: The formulation was prepared by ﬁlm hydration method. Release of drug was assessed at pH
1.2 and 7.4. Formulation was assessed for in vitro hepatoprotection on Chang liver cells,
lipopolysaccharide-induced reactive oxygen species (ROS) production by RAW 267.4 (murine
macrophages), in vivo efﬁcacy against paracetamol-induced hepatotoxicity and pharmacokinetic study
by oral route in Wistar rat.
Results: The formulation showed maximum entrapment (55%) for a lecithin–cholesterol ratio of 6:1.
Comparative release proﬁle of formulation was better than silymarin at pH 1.2 and pH 7.4. In vitro studies
showed a better hepatoprotection efﬁcacy for formulation (one and half times) and better prevention of
ROS production (ten times) compared to silymarin. In in vivo model, paracetamol showed signiﬁcant
hepatotoxicity in Wistar rats assessed through LFT, antioxidant markers and inﬂammatory markers. The
formulation was found more efﬁcacious than silymarin suspension in protecting the liver against
paracetamol toxicity and the associated inﬂammatory conditions. The liposomal formulation yielded a
three and half fold higher bioavailability of silymarin as compared with silymarin suspension.
Conclusions: Incorporating the phytosomal form of silymarin in liposomal carrier system increased the
oral bioavailability and showed better hepatoprotection and better anti-inﬂammatory effects compared
with silymarin suspension.
 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate /p h arepIntroduction
Silymarin, a hepatoprotective agent, obtained from single herb
Silybum marianum, is widely used in the treatment of liver diseases.
A mixture of ﬂavolignan isomers, namely silybin, isosilybin,
silydianin, silychristin is collectively expressed as silymarin [1].
Among these isomers, the most active component is silybin, which* Corresponding author at: Principal, Professor and Head-Department of
Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University,
Manipal, Karnataka 576104, India.
E-mail addresses: mallik.rao@manipal.edu, mallikin123@gmail.com (C.M. Rao).
1 Present address: Faculty of Pharmacy, AIMST University, Malaysia.
http://dx.doi.org/10.1016/j.pharep.2014.04.007
1734-1140/ 2014 Institute of Pharmacology, Polish Academy of Sciences. Published baccounts for 60–70% of the total content of silymarin and is
considered as the marker of silymarin [2].
Many experimental studies have proved the hepatoprotective
activity of silymarin [3]. One of the major limitations of silymarin is
poor oral-bioavailability. The oral absorption of silymarin is only
about 23–47% [4], leading oral bioavailability to 0.73% [5].
Therefore, a higher dose of silymarin is required to improve
therapeutic efﬁcacy. The reasons suggested for its poor bioavail-
ability includes the following: poor enteral absorption [6],
instability in gastric environment [4] and poor solubility [4]. Thus,
enhancement of bioavailability of silymarin is a challenging task.
Although substantial advancement has been made in improving
the bioavailability of silymarin through various dosage forms, littley Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Table 1
Optimization of lipid and drug ratio.
Formulation SPC:cholesterol:
drug (mg)
Molar ratio
(SPC:C)
% Entrapment
efﬁciency
L1 294:00:10 10:00 36.11
L2 255:15:10 09:01 32.84
L3 240: 15:10 08:01 18.69
L4 180:15:10 06:01 47.22
L5 240:30:10 04:01 32.22
L6 180:30:10 03:01 35.53
L7 180:77:10 1.5:1 11.06
SPC:cholesterol:drug ratio without freeze-drying at sonication of frequency – 80 Hz,
time – 2 min and pulse – 4 s.
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make silymarin target speciﬁc to promote hepatocytes’ regenera-
tion and to prevent inﬂammation in liver [7].
The process of repair in the liver is largely by the regeneration of
hepatocytes. However, inﬂammation in liver is one of the major
problems associated with hepatocyte toxicity. If inﬂammation is not
controlled sufﬁciently, the cellular phase of inﬂammation through
macrophages (Kupffer cells) and ﬁbroblast (stellate cells) promote
ﬁbrosis to replace dead cells [8]. Therefore, a formulation of
silymarin that would target the liver in general and inﬂammation in
particular would be beneﬁcial over a formulation of silymarin that
would just enhance the bioavailability of silymarin. In this context,
the present study is aimed at developing a formulation of silymarin
with the help of liposomal and phytosomal combination. This is
based on the fact that phytosomal silymarin is more stable in the
gastric environment [9] to enhance the bioavailability of silymarin
while the liposomal silymarin is having the highest ability to get
captured by macrophages, Kupffer cells and inﬁltrated WBC viz.,
neutrophil, monocytes, etc. through phagocytosis process and
modulate their actions [10]. This phenomenon makes silymarin in
formulation to target inﬂammation.
Materials and methods
Materials
Triton-X 100, trypsin and dithiothreitol (DTT) were purchased
from Himedia lab Pvt. Ltd. (Mumbai, India). Lecithin (Soya L-a-
Phosphatidylcholine or SPC), 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT), Dulbecco’s modiﬁed eagle’s
medium (DMEM), minimum essential medium (MEM), fetal
bovine serum (FBS) and silymarin were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). All other chemicals used in the
study were of analytical grade.
Cell lines
Chang liver cells and RAW 264.7 were purchased from National
Center for Cell Sciences (Pune, India).
Animals
Wistar rats of 4–6 weeks age, weighing 180–200 g were
selected for study. The animals were acclimatized to for one week
in controlled temperature and humidity conditions with 12:12 h
light and dark cycle. The rats were fed standard food pellets and
water ad libitum. The study was conducted after obtaining
clearance from the Institutional Animal Ethics Committee of KMC.Table 2
Optimization of various liposomal parameters for formulation L4.
Parameters Preformulation of liposome (SPC:C 6:1) 
Freeze drying NO Yes Yes 
Cryoprotectanta Nil Nil Mannitol 1
Yield 98% 98% 97% 
Particle size (nm) 100 701 1005 
Zeta potential >70 mV >70 mV >70 mV 
HPHb (Cycle, bars) NA 10, 15,000 10, 15,000
% Entrapment Sil A&B* 47.22 53.39 41.28 
Sil Ac NA 40.89 39.16 
Sil Bd NA 65.90 43.41 
* Average of Silybin A and Silybin B
a Amount in w/v.
b High pressure homogenization.
c Silybin A.
d Silybin B.Preparation of liposomes
Preformulation studies
Silymarin was evaluated for its physicochemical interaction
with lecithin (SPC) and cholesterol (C) at a ratio of 1:1:1 using
differential scanning calorimetry (DSC).
Development of silymarin-liposomes
Liposomes were prepared by lipid ﬁlm hydration method [11].
Silymarin (S) 10 mg, different quantities of SPC and cholesterol were
taken into a round bottom ﬂask and dissolved in methanol-
chloroform mixture (1:9) (Tables 1 and 2). Later the solvent was
evaporated under vacuum at 40 8C in a rotary evaporator to develop
thin ﬁlm. The solvent traces from ﬁlm was removed by drying
overnight in a vacuum desiccator. The ﬁlm was hydrated with
phosphate buffer saline (PBS, pH 7.4), containing varied amount of
cryoprotectant (mannitol and sucrose) (Table 2) at 100 RPM and at
50 8C for 1 h to prepare a liposomal suspension. The liposome vesicle
size was reduced under high-pressure homogenization at 20,000 psi
for 5 cycles. The liposomes were kept overnight in deep freezer at
80 8C. The frozen liposomes were lyophilized at reduced pressure
and stored at 4 8C in airtight containers for further experiments.
Physicochemical characteristics of liposomes
Particle size and zeta potential
Mean particle size, polydispersity index (PDI) and zeta potential
of liposomes were determined by Malvern NanoZS (Malvern
Instruments Ltd., Worcestershire, UK) after suitable re-dispersion
in water.
Drug entrapment efﬁciency in liposomes [12]
Liposomal suspension (1 ml) was centrifuged at 1000 rpm for
10 min to separate unentrapped particles. Supernatant was
collected and again centrifuged at 64,000  g at 4–8 8C forOptimized
Yes Yes Yes Yes
0% Sucrose 10% Mannitol 15% Sucrose 15% Sucrose 5%
95% 68.75% 75.63% 98.5%
400 1205 405 329
>70 mV >70 mV >70 mV 70.5 mV
 10, 15,000 15, 20,000 10, 20,000 10, 20,000
53.27 52.40 47.29 58.94
50.50 63.55 39.63 59.24
56.03 41.25 54.95 58.64
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separated and stored for testing free drug content. To the pellet,
100 ml of 10% Triton X and 900 ml of methanol were added. The
concentration of silymarin in supernatant and precipitate was
analyzed by reversed phase high performance liquid chromatog-
raphy (RP-HPLC). The HPLC column was Hibar1 RP C-18,
4.6 mm  250 mm from Merck, Darmstadt, Germany. The mobile
phase methanol: water (50:50, pH 3.5) was pumped at a ﬂow rate
of 1.0 ml/min. The detection wavelength and the detection limit of
silymarin adopted were 286 and 1 mg/ml respectively.
Morphology
Liposomes were suspended in water and particle shape was
visualized by transmission electron microscope (TEM), TECNAI 200
Kv TEM from Sophisticated analytical instrument facility, All India
Institute of Medical Sciences, New Delhi, India.
In vitro drug release [7]
The dissolution studies were carried out according to a
dissolution test of China Pharmacopoeia (2005 edition, paddle
method). The dissolution ﬂasks were immersed in a water bath at
37 8C. The dissolution medium (pH 7.4 (PBS)) and pH 1.2 (HCl)) were
continuously stirred at 100 rounds/min. Silymarin (77 mg), lipo-
some formulations (equivalent to 77 mg of Silymarin) were added to
the surface of the stirred dissolution medium at the beginning of the
study. At different time intervals, 10 ml samples were withdrawn
and ﬁltered using 0.22 mm syringe ﬁlter; while 10 ml fresh medium
were added into the ﬂask. Forty-microliter aliquot of the resulting
solution was injected into HPLC and detected at a wavelength of
286 nm; the concentration of silymarin was measured.
In vitro assessment
In vitro hepatoprotection
Silymarin and its liposome were compared for in vitro
hepatoprotection of Chang liver cells against paracetamol(para)-
induced heptotoxicity based on the principles of MTT cytotoxicity
[13]. Cells were pretreated with various concentrations of testing
samples in maintenance media for 24 h. Further, the cells were
challenged with 100 ml of 50 mM of paracetamol for 24 h. The
media were replaced with 100 ml of 1 mg/mL solution of MTT and
incubated for 4 h. The formed blue colored product (formazan) was
found to be proportional to the number of live cells.
% Viability ¼ 100  Absorbance of control  Absorbance of test
Absorbance of control
 100
 
Nuclear staining study
Two thousand cells were seeded per well into 24-well plates
with MEM containing 10% FBS. After 24 h, cells were treated with
7.5 mg/ml of the equivalent of silymarin and incubated for 24 h.
The media were removed and the plate was washed with PBS (pH
7.4). Paracetamol (100 ml of 50 mM) in complete media was added
and incubated for 24 h. Cells were ﬁxed with ice-cold methanol for
20 min. Cells were washed with PBS again and 50 ml of Hoechst
33342 stain (2 mg/ml) was added to each well. The plate was
incubated at 37 8C for 20 min. Finally, the plate was washed thrice
with PBS and observed under a ﬂuorescent microscope for
morphonuclear changes [14].
Effect on antioxidant status of Chang liver cells
Chang liver cells (1  106 per ml) were seeded in six well plates
for 24 h. Silymarin and its liposome were added at a concentrationof 7.80 mg/ml after 24 h. Cells (except from control well) were
stimulated with 50 mM paracetamol and incubated for 24 h. After
24 h, the media was removed and cells were lysed with cold buffer
and used for estimation of glutathione (GSH) content [15] and lipid
peroxidation (TBARS) levels [16].
Reactive oxygen species (ROS) inhibition assay
Murine macrophages ell line, RAW 264.7 cells were stimulated
for ROS production by lipopolysaccharide (LPS) [17]. Silymarin and
its liposome were studied using pretreatment in a concentration
range of 31–250 mg/ml equivalent to silymarin.
In vivo assessment
In vivo hepatoprotection
Hepatotoxicity was induced in Wistar rat with a minor
modiﬁcation of the method of Zakaria et al. [18]. The toxic dose
of paracetamol selected here was 2.75 g/kg p.o. instead of 3 g/kg
used by Zakaria et al. Brieﬂy, Wistar rats were randomly divided
into four groups containing six animals each viz., sham,
paracetamol (para) control, silymarin, liposome treatment group.
Caboxymethyl cellulose (CMC, 0.25%, w/v) was used as vehicle for
the oral administration of silymarin, silymarin-liposomes and
paracetamol. Silymarin and its liposomal formulations were
administered for seven days at doses that had the contents of
silymarin equivalent to 50 mg/kg. On day-6 of the study,
paracetamol was administered once at a dose of 2.75 g/kg to
induce hepatotoxicity. Forty-eight hours after the administration
of paracetamol, blood was withdrawn and serum was separated
to perform liver function tests (LFT). The effect was also studied
on kidney by monitoring serum urea and serum creatinine level,
and heart by monitoring creatine kinase level. The liver was
dissected out, a part of liver was used for antioxidant and
inﬂammatory marker study, and remaining part of liver was used
for histopathology.
Estimation of antioxidant parameters
10% of liver homogenate was made in 150 mM KCl. Homoge-
nate was centrifuged at 14,000 rpm for 15 min and used for the
estimation of antioxidant parameters viz., total thiols [15],
glutathione (GSH) [15], lipid peroxidation [16], catalase [19] and
super oxide dismutase (SOD) [20].
Estimation of inﬂammatory markers
Liver homogenate was used for estimation of interleukin-6 (IL-
6) level (using kits from Krishgen Biosystem, Mumbai, India),
nitrite level [21] and myeloperoxidase (MPO) level [22].
Bioavailability study in Wistar rats
The plasma concentration of silymarin (equivalent to combined
silybin) was determined by RP-HPLC. The chromatographic
conditions of HPLC were similar to analytical study. Twelve male
Wistar rats were divided into two groups. Animals were fasted for
8 h. Silymarin and its liposomal formulation were administered
orally after suspending them in 0.25%, w/v, CMC. The quantity of
silymarin that was administered had silybin at a level of 200 mg/
kg. Blood (250 ml) was withdrawn at the time points, viz., 15 min,
30 min, 1 h, and 2 h intervals. To 100 mL of separated plasma, 5 ml
of a-napthol was added as internal standard. The protein was
precipitated by the addition of 300 ml chilled methanol: acetoni-
trile (50:50). The mixture was centrifuged at 14,000 rpm for
10 min. 40 ml of supernatant was injected into the column. The
standard plot was made and the peak concentration, peak time,
AUC, and other pharmacokinetic parameters were calculated by
non-compartment modeling using WinNonline software, Phar-
sight Corporation, CA, USA.
Fig. 1. Characterization of liposome. (a) DSC thermogram, (b) TEM image, (c) release study silymarin and its liposomes at pH 1.2, (d) release study silymarin and its liposomes
at pH 7.4. All the values in (c) and (d), are mean  SEM of three readings.
Fig. 2. In vitro hepatoprotection in paracetamol-induced toxicity against Chang liver cells. All the values are mean  SEM of three tests in triplicate, ap < 0.05 compared to
silymarin.
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Fig. 3. Nuclear staining in paracetamol-induced toxicity on Chang liver cell line.
Arrows indicating condensed nuclei and cytoplasm shrinkage; concentration of
treatments: paracetamol – 50 mM, silymarin – 7.5 mg/ml, silymarin liposome –
7.5 mg/ml equivalent of silymarin. All the values are mean  SEM of three tests in
triplicate where ap < 0.05 compared to control, bp < 0.05 compared to para control.
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Statistical analysis of the data was carried out by one-way
ANOVA (Graph PAD Instat Software) followed by Tukey post hoc
test. A value of p < 0.05 was considered to be signiﬁcant.
Results
Preparation and characterization of silymarin-liposomes
Preformulation studies
Physical mixtures (silymarin and lipids) did not show any drug-
lipid interactions. They were stable, physically and chemically as
no changes were observed in the data of DSC (Fig. 1a).
Preparation of silymarin-liposomes
The encapsulation percentage of silymarin was found to be
maximum for formulation containing SPC and cholesterol at molar
ratio 6:1 (Table 1). Particle size obtained from sonication and high-
pressure homogenizer (HPH) was compared. More homogeneous
and uniform particles were obtained by HPH compared to
sonication alone. A pressure of 20,000 psi for 5 cycles was found
to be optimum for size reduction. Sucrose 5%, w/v, as cryoprotec-
tant produced more hygroscopic and lesser size (below 500 nm)
liposomes compared mannitol. This was selected as optimized
formulation (Table 2).
Transmission electron microscopy for surface morphology
After slightly shaking in water, a monolayer formed. Particles
appeared to be spherical in shape (Fig. 1b).
DSC analysis
DSC thermogram of silymarin showed an endothermic peak at
257.38 8C, while for liposomes, 207.66 8C. The shifts of endother-
mic peak of 40–50 8C in thermogram suggested a possible
interaction of silymarin with lipid components and could account
for enhanced entrapment (Fig. 1a).
In vitro drug release studies
Detection of silymarin was done based on the presence of
amount of silybin A and silybin B. Silymarin used in the study had
44.9 and 57.31% of silybin A and silybin B, respectively. The
dissolution amount was calculated on the average amount of
silybin A and silybin B. The release rate of the liposomes was
investigated by dissolution in gastric pH using HCl (pH 1.2) and
intestinal pH, using phosphate buffer saline (pH 7.4). At pH 1.2, the
liposomes showed an average cumulative drug release ofFig. 4. Antioxidant parameter in paracetamol-induced toxicity in Chang liver cells. All th
compared to para control, cp < 0.05 compared to silymarin.98.57  0.40% whereas silymarin alone was found to be
6.65  0.38% after 12 h (Fig. 1c). Conversely, at pH 7.4, the complete
release (86.80  2.87%) took place around 24 h later while fore values are mean  SEM of six animals where ap < 0.05 compared to sham, bp < 0.05
Table 3
Effect of treatments on ROS production by LPS on macrophage cell line.
Concentration (mg/ml) Silymarin Silymarin-liposome Lecithin equivalent
Percentage ROS inhibition
Mean  SEM Mean  SEM Mean  SEM
31.25 12.84  4.06 62.61  4.01 12.73  2.61
62.5 20.70  0.09 83.98  1.37 22.93  17.12
125 78.16  1.68 89.91  5.05 126.60  40.62
250 90.26  1.05 91.24  0.61 158.42  55.38
All the values are mean  SEM of three tests in triplicate.
Fig. 5. LFT in paracetamol-induced toxicity in Wistar rats. All the values are mean  SEM of six animals where ap < 0.05 compared to sham, bp < 0.05 compared to para control,
cp < 0.05 compared to silymarin.
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N. Kumar et al. / Pharmacological Reports 66 (2014) 788–798794silymarin the release was only 17.42  0.58% (Fig. 1d). Results
showed that the formulation has increased the solubility of the drug.
In vitro studies
In vitro hepatoprotection
CTC50 (concentration at which 50% cells die) value of silymarin
was found to be 151.2 mg/ml in Chang Liver cells. The dose of
paracetamol to cause hepatotoxicity to Chang liver cells was
50 mM. The liposomal formulation of silymarin was found to be
one and half-fold more active than silymarin in increasing
percentage viability (Fig. 2).
Nuclear staining study
Paracetamol treatment produced nuclear condensation, and a
disrupted membrane with cytoplasmic disintegration. The pre-
treatments of cells with silymarin liposomes showed better
prevention in these morphological changes associated with
paracetamol treatment (Fig. 3).
Estimation of antioxidant parameters
Paracetamol treatment depleted GSH levels in Cells and a
signiﬁcant increase in TBARS level in the cells. Treatment withFig. 7. Antioxidant parameter in paracetamol-induced toxicity in Wistar rats. All the v
compared to para control, cp < 0.05 compared to silymarin.
Fig. 6. Effect of silymarin and formulation on kidney and heart in paracetamol-induced t
compared to sham, bp < 0.05 compared to para control, cp < 0.05 compared to silymarin.silymarin and liposomes increased the GSH content of cells and
signiﬁcantly lowered the TBARS level. The TBARS lowering effect
was signiﬁcantly more for silymarin-liposome compared with
silymarin suspension (Fig. 4).
ROS inhibition assay
The liposomal preparation of silymarin was signiﬁcantly more
effective than silymarin in inhibiting LPS-stimulated ROS release
from the RAW 264.7 murine macrophages (IC507.93 and 98.86 mg/
ml respectively). Lecithin could not prevent ROS formation by RAW
264.7 (Table 3).
In vivo studies
In vivo hepatoprotection study
Effect on liver enzymes. The paracetamol challenge in control
animals raised AST level about two folds compared to sham
animals. Silymarin-liposomes treatment was signiﬁcantly effective
in preventing the paracetamol-induced rise in AST level, as it
brought the levels back to normal unlike the silymarin per se
treatment. Silymarin and its liposome pretreatment for 7 days
signiﬁcantly protected the liver against the paracetamol inducedalues are mean  SEM of six animals, where ap < 0.05 compared to sham, bp < 0.05
oxicity in Wistar rats. All the values are mean  SEM of six animals, where ap < 0.05
Fig. 8. Effects on Inﬂammatory markers. All the values are mean  SEM of six animals, where ap < 0.05 compared to sham, bp < 0.05 compared to para control.
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parameters (Fig. 5).
Effect of silymarin and its liposomes on kidney and heart. Parace-
tamol administration also affected the kidney function (increased
level of urea and creatinine in serum) of control rats. Silymarin and
its liposome prevented these changes. Silymarin-liposomes
showed better efﬁcacy compared to silymarin alone in preventing
the paracetamol-induced damage. No signiﬁcant changes were
observed in creatine kinase level (Fig. 6).
Estimation of endogenous antioxidant enzymes. A signiﬁcant deple-
tion in the antioxidant levels of liver was evidenced by a decline in
the levels of catalase, SOD, total thiols and glutathione levels
signiﬁcantly in paracetamol treated animals as compared with the
sham animals. The decline of antioxidant status correlated with a
signiﬁcant elevation of malonal dialdehyde (MDA) levels. Both,
silymarin and silymarin-liposomes signiﬁcantly reversed this
effect (Fig. 7).
Estimation of inﬂammatory markers. Paracetamol toxicity increased
IL-6 levels signiﬁcantly in liver homogenate of control animals
compared to sham animals. Silymarin-liposome signiﬁcantlyFig. 9. Histology of liver in paracetamol-induced toxicity in Wistar rats. ‘‘a’’ indicates sinuprevented the rise in IL-6 level and the activity was better than
silymarin suspension (Fig. 8). Nitrite levels in liver homogenate of
control animals increased signiﬁcantly compared to sham animals.
Liposomes signiﬁcantly prevented the elevation in nitrite level and
the activity was better than silymarin suspension (Fig. 8). Paraceta-
mol treatment signiﬁcantly raised the myeloperoxidase in liver
homogenate to 6.074 ng/mg of protein while in control animals it
was 1.015 ng/mg protein. Silymarin and its liposomes signiﬁcantly
prevented the elevation in MPO level (1.13 and 0.23 ng/mg of
protein, respectively). The activity of silymarin-liposomes was
comparatively better than silymarin suspension (Fig. 8).
Histopathology. Paracetamol intoxication showed fatty accumula-
tion in hepatocyte. The central vein of the liver of paracetamol
treated animals showed dilatation and congestion in sinusoids as
compared with the sham animals. Treatment with silymarin at
50 mg/kg partially prevented fatty accumulation, while it failed in
preventing the congestion in sinusoids and dilatation in the central
vein. However, the silymarin-liposome pretreatment prevented all
these changes of liver caused by paracetamol toxicity (Fig. 9).
Bioavailability studies in male Wistar rats. Silybin, the marker of
silymarin, in plasma was separated by protein precipitationsoids, ‘‘b’’ indicates central vein, and ‘‘c’’ indicates fatty accumulation in hepatocyte.
Fig. 10. Pharmacokinetic study. Typical chromatogram silymarin: (a) blank Wistar rat plasma, (b) spiked silybin and a-napthol, (c) a sample after oral administration of
silymarin; (d) area under curve for silybin in silymarin and liposomes. All the values are mean  SEM of six rats.
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Table 4
Pharmacokinetic parameters of silymarin (equivalent to silybin).
Pharmacokinetics
parameters (unit)
Silymarin Liposome
Mean  SEM Mean  SEM
Cmax (ng/ml) 136.52  20.54 716.40  42.85
tmax (h) 0.50  0.0 0.50  0
AUC0–2 (h*ng/ml) 115.20  5.99 436.35  21.59
AUC0–inf (h*ng/ml) 158.83  5.25 499.66  23.40
Elimination rate constant
(Ke) (1/h)
0.54  0.06 1.04  0.04
Half-life (h) 1.28  0.17 0.67  0.03
AUMC0–t (h*h*ng/ml) 103.04  4.82 339.98  14.82
AUMC0–inf (h*h*ng/ml) 258.89  13.46 534.44  19.97
Clearance (ml/h) 1266.02  41.41 404.61  18.59
Volume of distribution
(Vd) (ml)
1946.93  177.34 435.41  24.8
Mean Residence time0–t
(MRT) (h)
0.9  0.009 0.78  0.006
MRT0–inf (h) 1.64  0.09 1.07  0.01
All the values are mean  SEM of six animals.
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isomers, silybin A and silybin B, two peaks were obtained at 17.7
and 19.8 min. a-Napthol was used as internal standard with a
recovery of 98%. The standard curve of silybin was prepared in the
range of 30 ng/ml to 10 mg/ml, which was linear (r2 0.9999).
Average of the peak areas of both isomers was considered for
analytical purpose. Typical chromatograms are displayed in
Fig. 10a–c.
Concentration-time graph of silybin was plotted after oral
administration of silymarin and its liposomal formulation
(Fig. 10d). AUC0–2 of formulation was more than three and half
times higher than silymarin suspension. The Cmax obtained from
the bioavailability study was 136.52  20.54 ng/ml for silybin,
with a tmax of 0.5 h. The Cmax was increased by liposomal
formulation to 716.40  42.85 ng/ml without a change in tmax
(Table 4).
Discussion
The optimized liposome of silymarin was spherical in shape and
homogeneous in particle size distribution. Zeta potential of
formulation (70 mV) was found to be more than optimum for
physical stability of the formulation [23]. DSC thermogram of
liposomal formulation showed that there was an interaction
between the lipid and drug, as the peak of silymarin shifted
signiﬁcantly by more than 40 8C. This interaction suggested the
formation of phytosomes. The formulation had increased the
solubility of silymarin at both tested pH compared to silymarin
alone solubility.
Incubation of paracetamol with Chang liver cells resulted in
reduction of cell viability while pretreatment with silymarin-
liposomes signiﬁcantly increased the percentage cell-viability as
compared to silymarin suspension. The nuclear staining images
also conﬁrmed that the liposomes had a better role. The decreased
level of GSH and high TBARS reﬂected the toxic effect of
paracetamol, which was signiﬁcantly prevented by silymarin-
liposomes and, to a lesser extent, by silymarin suspension.
At a large acute dose, paracetamol causes hepatotoxicity by
forming a large quantity of toxic metabolite N-acetyl-p-benzoqui-
none imine, which gets detoxiﬁed in the body by the formation of a
conjugate, 3-glutathion-S-ylacetaminophen and results in deple-
tion of endogenous antioxidants, mainly the GSH. Subsequently
the non-metabolized toxic product covalently binds with protein
and causes toxicity [24]. Similar ﬁndings were obtained in the
present study. Paracetamol treatment depleted glutathione levelalmost by six folds, which was prevented by silymarin and its
liposomes treatment. This sharp decline in glutathione was also
associated with increased oxidative stress conditions like decline
in antioxidant enzymes viz., catalase, SOD and rise in MDA levels.
Except SOD, other antioxidant parameters were signiﬁcantly
normalized by silymarin-liposomes to a greater degree than
silymarin suspension.
As suggested by Pumford et al. [25], the toxic adduct with
protein results in membrane damage and can be correlated with a
rise in AST, ALT and mild increase in bilirubin levels. In the present
study similar ﬁndings has been obtained. Silymarin and its
liposomes signiﬁcantly prevented these changes. The paracetamol
intoxication resulted in centrilobular necrosis and ballooning in
hepatocytes of liver parenchyma, which were minimized by
pretreatment with silymarin and its liposomes. Paracetamol
intoxication also resulted in kidney damage, marked by increased
serum urea and creatinine levels [26]. The liposomes were
signiﬁcantly more effective than silymarin in normalizing the
elevated urea levels, which indicated that the carrier systems
might have increased the nephroprotective effect of silymarin
together with hepatoprotective action.
Paracetamol intoxication increased the level of IL-6, which
indicated inﬂammatory status of liver. Rise in the level of MPO
indicated increased activity of inﬂammatory cells viz., neutrophil,
lymphocytes and Kupffer cells. This was also supported by a rise in
nitrite level. Liposomes showed better activity in combating these
inﬂammatory conditions as compared with silymarin suspension.
This can be justiﬁed by the fact that Kupffer cells actively take up
liposomes. Thus, silymarin in liposomal carrier system might have
targeted inﬂammatory cells resulted in increased anti-inﬂamma-
tory activity.
The above ﬁndings were supported by increased bioavailability
of silybin from silymarin extract. Cmax of liposomal silybin
increased more than ﬁve times, with no change in tmax. More
than threefold increase was observed in AUC level. Decrease in
half-life and increase elimination rate constant can be justiﬁed by
selective clearance of liposome by Kupffer cells.
Conclusion
Incorporating phytosomal form of silymarin in liposomal
carrier system showed better in vitro and in vivo hepatoprotection
besides showing better anti-inﬂammatory effects and improve-
ment in histopathological changes as compared to silymarin
suspension. These effects were further supported by increase in
AUC and Cmax of silybin by silymarin-liposomes compared to
silymarin suspension.
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